News & Events – Page 3 – Sumitovant

Select Company

September 03, 2021Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the Virtual 2021 Annual Meeting of the American Urological Association
September 01, 2021Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference
August 26, 2021Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia
August 18, 2021Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the 2021 Annual Meeting of the American Urological Association
August 12, 2021Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer
August 12, 2021Urovant Sciences Appoints Betzy Estrada as Executive Vice President and Chief Human Resources Officer
August 04, 2021Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)
July 29, 2021Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive Bladder
July 28, 2021Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates
July 20, 2021Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
« Previous 1 2 3 4 5 … 21 Next »